Blood Glucose and Hormone Changes in Post-Chronic Pancreatitis Diabetes
Data Collection
Collected at a single point in time - Cross-sectionalChronic Disease+10
+ Diabetes Mellitus
+ Digestive System Diseases
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Summary
Study start date: February 11, 2025
Actual date on which the first participant was enrolled.The benefits of this study to participants include: 1. It will help to make early diagnosis or risk screening for the potential related risks and concomitant diseases of the disease; 2. Provide necessary suggestions for the treatment and intervention of the disease, or provide useful information for the related research of the disease. 3. We will provide Abbott version h dynamic glucose meter and assessment of internal and external secretion function. The researcher will provide professional endocrine related lifestyle and drug guidance for the subjects according to their CGMS data. The risks that this study may bring to participants are: There may be some very small risks in specimen collection, including transient pain, local cyanosis, etc. a few people will have mild dizziness or extremely rare needle infection.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.2000 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Male or female Chinese subjects; * Was ≥ 18 years old when signing the informed consent; * Patients with complete diagnosis of chronic pancreatitis; ④ Those who voluntarily signed informed consent; ⑤ Those who complete serum samples in multiple centers and put them into storage. Exclusion Criteria: * Patients with impaired glucose tolerance but undiagnosed diabetes; * Patients with T1DM related autoimmune markers or other types of DM; * Patients with autoimmune pancreatitis, recurrent acute pancreatitis or acute onset of chronic pancreatitis; * Patients who underwent pancreatic surgery or related invasive procedures during treatment; * Previous or current malignant tumor; ⑥ Pregnancy or lactation; ⑦ Suffering from severe heart, liver or kidney dysfunction or malignant disease; ⑧ Failure to sign informed consent for cognitive impairment or other reasons.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives